Wegovy is a brand name for semaglutide, a medication used for chronic weight management in adults who have obesity or are overweight and have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), similar to tirzepatide. It works by mimicking the action of the GLP-1 hormone, which helps regulate appetite, food intake, and body weight.

Wegovy is administered as a once-weekly subcutaneous injection. Clinical trials have shown that it can lead to significant weight loss when used as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. Some studies have demonstrated that people using Wegovy have achieved up to 15% or more weight loss compared to placebo.

As with any medication, Wegovy may cause side effects, which can include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, fatigue, and others. It's important for individuals considering Wegovy to discuss its potential benefits and risks with a healthcare provider before starting treatment.

Wegovy was approved by the U.S. Food and Drug Administration (FDA) in June 2021 and is available by prescription. It represents a significant advancement in the treatment of obesity and overweight, offering a new option for individuals struggling to lose weight through lifestyle changes alone. However, it's essential to remember that Wegovy is not a standalone solution and should be used in conjunction with a healthy diet, increased physical activity, and other lifestyle modifications to achieve and maintain weight loss.